A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects With Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects With Stargardt Disease

The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease

开始日期2024-07-31

申办/合作机构

Belite Bio, Inc.

ACTRN12623001328662

/ Active, not recruiting临床2期IIT

An Open-Label, Single-Arm, 2-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Subjects with Stargardt Disease

开始日期2023-11-14

申办/合作机构

RBP4 Pty Ltd

NCT05949593

/ Recruiting临床3期

PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)

This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.

开始日期2023-07-27

申办/合作机构

Belite Bio, Inc.

100 项与 Tinlarebant 相关的临床结果

登录后查看更多信息

100 项与 Tinlarebant 相关的转化医学

登录后查看更多信息

100 项与 Tinlarebant 相关的专利（医药）

登录后查看更多信息

项与 Tinlarebant 相关的文献（医药）

2021-12-01·European journal of medicinal chemistry1区 · 医学

Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development

1区 · 医学

Review

作者: Kim, Noheul ; Priefer, Ronny

Retinol-binding protein 4 (RBP4) is a serum protein that transports Vitamin A. RBP4 is correlated with numerous diseases and metabolic syndromes, including insulin resistance in type 2 diabetes, cardiovascular diseases, obesity, and macular degeneration. Recently, RBP4 antagonists and protein synthesis inhibitors are under development to regulate the effect of RBP4. Several RBP4 antagonists, especially BPN-14136, have demonstrated promising safety profiles and potential therapeutic benefits in animal studies. Two RBP4 antagonists, specifically tinlarebant (Belite Bio) and STG-001 (Stargazer) are currently undergoing clinical trials. Some antidiabetic drugs and nutraceuticals have been reported to reduce RBP4 expression, but more clinical data is needed to evaluate their therapeutical benefits. As regulating RBP4 levels or its activities would benefit a wide range of patients, further research is highly recommended to develop clinically useful RBP4 antagonists or protein synthesis inhibitors.

2020-01-01·Topics in Medicinal Chemistry

Recent Developments in Agents for the Treatment of Age-Related Macular Degeneration and Stargardt Disease

作者: Konstantin Petrukhin

A review.Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in older individuals living in developed countries.There are two major clin. presentations of AMD: atrophic or "dry" and neovascular or "wet." Geog. atrophy (GA) is the most severe manifestation of dry AMD which represents the form of the disease characterized by the highest prevalence.A smaller fraction of AMD patients (10-20%) develop choroidal neovascularization (CNV) which represents the key feature of neovascular AMD.Historically, laser photocoagulation, surgery, and photodynamic therapy were the first treatment options for patients with CNV.In recent years, the emergence of anti-VEGF therapeutics has transformed the treatment of patients with neovascular AMD.Current anti-VEGF biologics that represent a standard of care (ranibizumab, bevacizumab, and aflibercept) are very effective in improving or maintaining visual acuity in CNV patients over long periods of time.The work on the new generation of anti-VEGF agents with higher potency and long-lasting efficacy is ongoing with the goal of reducing the frequency of intravitreal injections required for achieving good visual acuity outcomes.Brolucizumab, abicipar pegol, and faricimab exemplify the efforts toward the development of novel therapeutic agents with lower frequency of intravitreal injections.While neovascular AMD can be effectively managed with current anti-VEGF therapeutics, there are no FDA-approved treatments for the atrophic form of AMD.Similarly, there is no therapy for inherited Stargardt disease, an orphan genetic form of macular dystrophy that shares phenotypic similarities with atrophic AMD.Due to the multigenic and multifactorial nature of AMD, it is believed that a combination of several factors may contribute to pathogenesis of atrophic AMD.This includes a complement system dysregulation in the retina and exposure of retinal cells to toxins produced in the visual retinoid cycle reactions (lipofuscin bisretinoids and retinaldehydes).Several therapeutic agents are currently being evaluated in clin. trials for geog. atrophy related to atrophic AMD or Stargardt disease.This includes pegcetacoplan (C3 inhibitor), avacincaptad pegol (C5 inhibitor), emixustat (RPE65 inhibitor), ALK-001 (deuterated form of vitamin A: C20-D3-retinyl acetate), STG-001 (RBP4 antagonist), and tinlarebant (RBP4 antagonist).These ongoing clin. trials may yield a therapy that will address a significant unmet medical need that exists for the currently untreatable forms of macular degeneration.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Stargardt’s Disease: Molecular Pathogenesis and Current Therapeutic Landscape

Review

作者: Upadhyay, Arun ; Dayma, Kunal ; Rajanala, Kalpana

Stargardt’s disease (STGD1) is an autosomal recessive juvenile macular degeneration caused by mutations in the ABCA4 gene, impairing clearance of toxic retinoid byproducts in the retinal pigment epithelium (RPE). This leads to lipofuscin accumulation, oxidative stress, photoreceptor degeneration, and central vision loss. Over 1200 pathogenic/likely pathogenic ABCA4 variants highlight the genetic heterogeneity of STGD1, which manifests as progressive central vision loss, with phenotype influenced by deep intronic variants, modifier genes, and environmental factors like light exposure. ABCA4 variants also show variable penetrance and geographical prevalence. With no approved treatment, investigational therapies target different aspects of disease pathology. Small-molecule therapies target vitamin A dimerization (e.g., ALK-001), inhibit lipofuscin accumulation (e.g., soraprazan), or modulate the visual cycle (e.g., emixustat hydrochloride). Gene therapy trials explore ABCA4 supplementation including strategies like RNA exon editing (ACDN-01) and bioengineered ambient light-activated OPSIN. RORA gene therapy (Phase 2/3) addresses oxidative stress, inflammation, lipid metabolism, and complement system dysregulation. Trials like DRAGON (Phase 3, tinlarebant), STARLIGHT (phase 2, bioengineered OPSIN) show promise, but optimizing efficacy remains challenging. With the key problem of establishing genotype–phenotype correlations, the future of STGD1 therapy may rely on approaches targeting oxidative stress, lipid metabolism, inflammation, complement regulation, and genetic repair.

项与 Tinlarebant 相关的新闻（医药）

2025-11-03

·GlobeNewswire-Health Care

Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

MHRA response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 Nov. 02, 2025 -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has agreed to accept a Conditional Marketing Authorization application for Tinlarebant for the treatment of Stargardt disease based on the interim analysis results from the Phase 3 DRAGON trial. “We are extremely pleased with the outcome of our engagement with the MHRA. This is an incredibly exciting time for the Belite team as we see our perseverance bringing us closer to offering an effective therapy to patients living with Stargardt disease, who currently have no approved treatment options,” said Dr. Tom Lin, Chairman and CEO of Belite Bio. “We look forward to continuing our work with regulatory authorities as we advance Tinlarebant through late-stage development and toward the possibility of delivering the first approved therapy for this devastating disease.” “With consistent feedback from major agencies across the world, we are encouraged that the DRAGON trial provides a strong foundation for global submissions and potential approvals,” said Dr. Hendrik Scholl, Chief Medical Officer of Belite Bio. MHRA’s response is based on the interim analysis results which fulfil the criteria for a Conditional Marketing Authorization application. The Company remains on track to report final topline data from the Phase 3 DRAGON trial in the fourth quarter of 2025. These results are expected to be submitted to the MHRA for full Marketing Authorization Application. The pivotal Phase 3 DRAGON trial is a randomized, double-masked, placebo-controlled, global study designed to evaluate the safety and efficacy of Tinlarebant in adolescent patients with Stargardt disease. The trial enrolled 104 subjects across 11 jurisdictions, including the U.S., United Kingdom, Germany, France, Belgium, Switzerland, Netherlands, China, Hong Kong, Taiwan, and Australia, with a 2:1 randomization (Tinlarebant:placebo). The primary efficacy endpoint is the growth rate of atrophic lesions, alongside the assessment of safety and tolerability. Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in STGD1 and also contribute to disease progression in geographic atrophy (GA), or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Breakthrough Therapy Designation, Fast Track Designation and Rare Pediatric Disease designation in the U.S., Orphan Drug Designation in the U.S., Europe, and Japan, and Sakigake (Pioneer Drug) Designation in Japan for the treatment of STGD1. Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as STGD1 and GA in advanced dry AMD, in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. The content above comes from the network. if any infringement, please contact us to modify.

孤儿药快速通道突破性疗法

2025-10-22

·淮议大眼睛

分享部分眼病治疗的进展

1.基因治疗的基本认识视频来源：蔻德罕见病中心视频来源：尹哥聊基因 2.基因治疗进展（1）国内：RPGR基因突变相关视网膜色素变性，ND4基因突变引起的Leber遗传性视神经病变。建议关注医院临床试验和公司动态。国内治疗X连锁视网膜色素变性患者黄斑、视野及视敏度等明显改善 Leber遗传性视神经病变ND4基因治疗药临近获批上市患者招募丨NR082眼用注射液治疗莱伯氏遗传性视神经病变患者招募 RPGR基因变异相关的X连锁视网膜色素变性男性患者招募（2）国外：CEP290基因突变相关Leber先天性黑蒙症10型，PDE6B双等位基因突变相关视网膜色素变性，CHM基因突变相关无脉络膜症，GUCY2D基因突变相关Leber先天性黑蒙症I型，LCA5基因突变相关Leber先天性黑蒙症5型。因为在国外做临床试验，国内患者很难用上，建议关注药物引进及上海市一、上海五官科、北京协和、北京同仁医院等大医院的临床试验的动态。 Leber莱伯先天性黑蒙症LCA10重启3期临床试验，望取得更好的结果视网膜色素变性PDE6B有新突破显著的视觉功能显著恢复、视网膜结构改善无脉络膜症CHM的基因治疗已经获得FDA 和EMA授予的孤儿药指定 Leber先天性黑朦1型（LCA1）的基因疗法ATSN-101 Leber 先天性黑蒙5 型（LCA5）首个基因疗法大进展及BEST1基因临床招募 3.光遗传学药物进展（1）ZM-02：中眸科技在在美国眼科学会（AAO）年会发表ZM-02光遗传学基因疗法治疗研究效果的口头报告，展示患者从失明到能够独立完成日常活动——甚至重新骑行的转变。但目前ZM-02药物属于IIT 研究者发起的临床研究活动，ZM-02尚未开展正式的注册临床实验。请大家持续关注该药物动态。失明到重新骑行！中国RP广谱疗法效果发布ZM-02光敏蛋白治视网膜色素变性RP （2）GA001：健达九州公司自主研发、治疗视网膜色素变性的基因治疗药物GA001注射液，在前期临床研究中已展现出良好的安全性，经美国食品药品监督管理局（FDA）评估，目前已正式获得临床试验许可，获准开展临床II期有效性与安全性研究。在中国，GA001注射液在北京天坛医院开展的研究者发起的临床研究（IIT）已于2024年1月完成首例受试者入组及给药。患者可咨询医院或公司国内有无进一步的招募计划。健达九州GA001管线获FDA批准进入II期临床（3）UGX202： UGX202作为跨基因突变的“通用型”创新基因疗法，可突破了罕见病患者数量限制，适用于多个疾病人群，包括视网膜色素变性、Stargardt病、无脉络膜症、及晚期干性年龄相关黄斑病变等。2025年10月9日，药物研发公司星明优健宣布与英国生物科技公司AviadoBio达成战略协议，授予其光遗传学管线UGX202海外独家开发和商业化的独家选择权。由此可看出该药物的国际认可度。在国内，2025年7月，星明优健、与复旦大学附属眼耳鼻喉科医院共同发起了一项光遗传学管线UGX202的研究者发起的临床研究。招募晚期RP患者，期望未来能够为国内晚期RP患者带来具有显著临床获益。【招募】晚期视网膜色素变性临床研究受试者星明优健授予AviadoBio光遗传学管线UGX202海外权益的独家选择权（4）NPI-001（N-乙酰半胱氨酸酰胺）： NPI-001 是专有的GMP 级 N-乙酰半胱氨酸酰胺 (NACA) 片剂，旨在治疗与视网膜色素变性 (RP) 等疾病相关的氧化应激。NPI-001 配方为稳定的片剂，易于患者自行服用，具有完善的生产工艺和方便的包装选择。2025年10月2日，美国食品药品监督管理局 (FDA) 授予 NPI-001片剂突破性疗法认定 (BTD)。该认定代表FDA认可了NPI-001 的早期临床证据，NPI-001 有望成为视网膜色素变性患者普适性药物。 Nacuity Pharmaceuticals N-乙酰半胱氨酸酰胺片剂获得美国 FDA 突破性疗法认定，用于治疗视网膜色素变性（5）Tinlarebant：研发公司Belite Bio, Inc.公司，2025年10月16日宣布，中国国家药品监督管理局（NMPA）药品审评中心已同意接受Tinlarebant 用于治疗 Stargardt 病的新药申请（NDA），并对其实施优先审查，该申请基于 3 期 DRAGON 试验的中期分析结果。以上3期DRAGON试验是一项随机、双盲、安慰剂对照的全球性研究，旨在评估Tinlarebant在青少年Stargardt病患者中的安全性和有效性。该试验入组了来自11个国家和地区的104名受试者，包括美国、英国、德国、法国、比利时、瑞士、荷兰、中国大陆、中国香港、中国台湾和澳大利亚，随机分组比例为2:1（Tinlarebant组：安慰剂组）。主要疗效终点是萎缩性病变的生长速度，并评估安全性和耐受性。目前中期结果显示3期DRAGON试验的主要终点具有统计学意义。3期如果成功，将为 Stargardt 病患者带来首个治疗方案。倍亮生物宣布，中国国家药品监督管理局根据Tinlarebant治疗Stargardt病的中期分析结果批准其新药申请并给予优先审评 3.新技术-无线视网膜芯片 2025年10月20 日在《新英格兰医学杂志》（NEJM）发表研究称：“通过在眼后植入微型无线芯片，并配合先进眼镜，晚期年龄相关性黄斑变性（AMD）患者的视力得到了部分恢复。” 据该团队介绍，在 32 名完全失明的植入者中，有 27 人在术后一年恢复了阅读能力。开创性的眼部植入物如何帮助盲人患者再次阅读 BYE BYE 有任何问题，可留言或私信，看到会回复的~ 关注我们轻松学习眼科/眼病的知识

基因疗法临床3期孤儿药上市批准临床结果

2025-10-15

·GlobeNewswire-Health Care

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

NMPA’s response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has agreed to accept the New Drug Application (NDA) with priority review for Tinlarebant for the treatment of Stargardt disease based on the interim analysis results from the Phase 3 DRAGON trial. “Having China NMPA agreed to review the NDA based on interim Phase 3 data is a remarkable milestone for Belite Bio and the Stargardt community,” said Dr. Tom Lin, Chairman and CEO of Belite Bio. “This milestone underscores the strength of the program and the urgent need for therapies in this devastating disease, where no approved treatment options exist. This achievement positions Belite Bio to advance Tinlarebant through the final stages of development and, if successful, bring the first treatment to people living with Stargardt disease.” NMPA’s response is based on the interim analysis results showing statistical significance in the primary endpoint of the Phase 3 DRAGON trial. The Company remains on track to report final topline data from the Phase 3 DRAGON trial in the fourth quarter of 2025. These results are expected to be submitted to the NMPA as part of the NDA that is currently under preparation in accordance with China CDE’s guidance. The pivotal Phase 3 DRAGON trial is a randomized, double-masked, placebo-controlled, global study designed to evaluate the safety and efficacy of Tinlarebant in adolescent patients with Stargardt disease. The trial enrolled 104 subjects across 11 jurisdictions, including the U.S., United Kingdom, Germany, France, Belgium, Switzerland, Netherlands, China, Hong Kong, Taiwan, and Australia, with a 2:1 randomization (Tinlarebant:placebo). The primary efficacy endpoint is the growth rate of atrophic lesions, alongside the assessment of safety and tolerability. About Tinlarebant (a/k/a LBS-008)Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in STGD1 and also contribute to disease progression in geographic atrophy (GA), or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Breakthrough Therapy Designation, Fast Track Designation and Rare Pediatric Disease designation in the U.S., Orphan Drug Designation in the U.S., Europe, and Japan, and Sakigake (Pioneer Drug) Designation in Japan for the treatment of STGD1. About Belite BioBelite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as STGD1 and GA in advanced dry AMD, in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com. Important Cautions Regarding Forward Looking StatementsThis press release contains forward-looking statements about future expectations and plans, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio’s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, the ability of Tinlarebant to treat Stargardt disease and geographic atrophy, and any other statements containing the words “expect”, “hope” and similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Belite Bio’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the timing to complete relevant clinical trials and/or to receive the interim/final data of such clinical trials; the timing to submit trial data to regulatory authorities for drug approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio’s drug candidates; the potential efficacy of Tinlarebant, as well as those risks more fully discussed in the “Risk Factors” section in Belite Bio’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Media and Investor Relations Contact:Jennifer Wu ir@belitebio.com Julie Fallonbelite@argotpartners.com

临床3期申请上市优先审批快速通道突破性疗法

100 项与 Tinlarebant 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
斯塔加特病	英国	Belite Bio, Inc.	2025-11-02

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
地图样萎缩	临床3期	美国	Belite Bio, Inc.	2023-07-27
地图样萎缩	临床3期	中国	Belite Bio, Inc.	2023-07-27
地图样萎缩	临床3期	澳大利亚	Belite Bio, Inc.	2023-07-27
地图样萎缩	临床3期	捷克	Belite Bio, Inc.	2023-07-27
地图样萎缩	临床3期	法国	Belite Bio, Inc.	2023-07-27
地图样萎缩	临床3期	瑞士	Belite Bio, Inc.	2023-07-27
地图样萎缩	临床3期	中国台湾	Belite Bio, Inc.	2023-07-27
地图样萎缩	临床3期	英国	Belite Bio, Inc.	2023-07-27
年龄相关性黄斑变性	临床1期	中国	倍亮生技医药（上海）有限公司	2025-06-06
干性年龄相关性黄斑病变	临床1期	澳大利亚	Belite Bio, Inc.	2022-11-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EURETINA2024	N/A	斯塔加特病	-	Tinlarebant 5 mg/day	築艱遞餘繭夢築糧餘製(衊簾艱鬱鹹糧築餘繭憲) = Delayed dark adaptation (9 of 13 subjects [69.2%]) were most frequently reported 願壓衊遞壓襯繭構膚鑰 (窪築獵觸廠糧積簾築製 ) 更多	-	2024-09-19
ACTRN12623001328662 (NEWS 1 \| NEWS 2 \| ARVO2024)	临床2期	斯塔加特病	12	Tinlarebant	衊鑰艱壓壓醖簾餘網餘(獵壓製鏇餘鏇艱餘製廠) = 獵夢鑰遞餘網網廠觸鹹顧膚襯網夢願獵構鏇網 (蓋淵獵顧鑰淵鹽簾網淵 )	积极	2024-05-05
NCT06388083 (DRAGON II, NEWS)	临床2/3期	斯塔加特病	-	Tinlarebant	壓鹹壓築襯製繭廠製壓(淵築廠衊繭艱鹹範鏇獵) = 壓齋願鏇繭鹽廠夢醖鬱築鏇窪構獵醖鏇簾鹽製 (醖夢構鹹襯選選築顧壓 )	积极	2024-05-01
NCT06388083 (DRAGON II, NEWS)	临床2/3期	斯塔加特病	-	安慰剂	-	积极	2024-05-01
NCT05266014 (LBS-008-CT02, ARVO 12023 \| ARVO 22023) 人工标引	临床1/2期	斯塔加特病	13	Tinlarebant	衊膚鏇餘蓋廠鹽築遞繭(壓襯壓獵夢醖選鏇蓋鏇) = 糧構衊繭壓獵範鹽衊製選淵築窪築範鹹蓋構窪 (簾糧淵築積鏇網鏇襯觸 ) 更多	积极	2023-04-23
NCT05266014 (Corporate Publications) 人工标引	临床1/2期	斯塔加特病	13	LBS-008	顧顧觸蓋窪製範窪艱獵(築鏇窪憲艱範蓋淵鹽繭) = 願衊鑰範構願憲膚壓齋選積遞糧願積簾餘遞衊 (餘淵艱鏇餘構製壓鹹醖 ) 更多	积极	2022-10-01